OpenNashEarnings

Dexcom (DXCM) · Medical Devices

Dexcom Q2 2026 earnings: summary, key numbers & outlook

Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026

Slides (10 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Dexcom's CONNECT trial showed CGM benefits for type 2 diabetes patients not on insulin, while a Stelo app relaunch and Nutrisense acquisition push it toward broader, consumer-facing glucose sensing.

Dexcom's main product news this quarter was clinical and consumer. The CONNECT randomized controlled trial found that CGM use in people with type 2 diabetes not using insulin improved glucose control compared with routine care. Dexcom also began launching a reimagined Stelo app with AI-driven insights and better food logging, and completed the acquisition of Nutrisense. International revenue grew 19% reported, outpacing the U.S.

Management is steering toward a much larger user base, citing about 9 million people in the U.S. who have CGM coverage but don't use it, and a long-term outlook through 2030 presented at Investor Day. The plan depends on converting nearly 50% of the U.S. base to G7 15 Day by year end, extending coverage, and a CMS decision expected this year. The tension is that growth rests on payer and regulatory decisions outside Dexcom's control.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Slides & documents

Open the slide deck (PDF, 10 pages) ↗

Dexcom Q2 2026 slide deck, page 1Dexcom Q2 2026 slide deck, page 2Dexcom Q2 2026 slide deck, page 3Dexcom Q2 2026 slide deck, page 4Dexcom Q2 2026 slide deck, page 5Dexcom Q2 2026 slide deck, page 6

Showing the first 6 of 10 pages.

From Dexcom investor relations

SEC filing

Key numbers

Revenue · GAAP
$1.308 billion

up 13% from a year ago on a reported basis

Net income · GAAP
$249.1 million

up from $179.8 million a year ago

Diluted EPS · GAAP
$0.64

up from $0.45 a year ago

Non-GAAP diluted EPS · non-GAAP
$0.70

up from $0.48 a year ago

Gross margin · GAAP
63.4%

up from 59.5% a year ago

Operating income · GAAP
$318.3 million

up from $212.6 million a year ago

Operating margin · GAAP
24.3%

up 590 basis points from a year ago

Segment or metricValueChange
U.S. revenue$933.4Mup 11% from a year ago
International revenue$375.0Mup 19% reported, 16% organic
Where each number comes from
  • Revenue: “Revenue grew 13% year-over-year to $1.308 billion on a reported basis and 12% year-over-year on an organic1 basis.”
  • Net income: “GAAP net income was $249.1 million, or $0.64 per diluted share, for the second quarter of 2026, compared to GAAP net income of $179.8 million”
  • Diluted EPS: “GAAP net income was $249.1 million, or $0.64 per diluted share, for the second quarter of 2026, compared to GAAP net income of $179.8 million”
  • Non-GAAP diluted EPS: “Non-GAAP net income* was $269.1 million, or $0.70 per diluted share, for the second quarter of 2026”
  • Gross margin: “GAAP gross profit totaled $830.0 million or 63.4% of revenue for the second quarter of 2026, compared to $688.8 million or 59.5% of revenue”
  • Operating income: “GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025.”
  • Operating margin: “GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025.”
  • U.S. revenue: “Total revenue | $933.4 | $375.0 | $1,308.4 | $841.0 | $316.1 | $1,157.1 Six Months Ended June 30, 2026”
  • International revenue: “Total revenue | $933.4 | $375.0 | $1,308.4 | $841.0 | $316.1 | $1,157.1 Six Months Ended June 30, 2026”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$1.3B+13.1%+9.8%
Operating income$318.3M+49.7%+24.7%
Net income$249.1M+38.5%+24.9%
Diluted EPS$0.64+42.2%+25.5%
Free cash flow$184.5M−11.7%−58.9%
Gross margin63.4%+3.9 pts+0.5 pts
Operating margin24.3%+5.9 pts+2.9 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenuefiscal year 2026$5.18 - $5.25 billion
Non-GAAP gross profit marginfiscal year 2026approximately 64%
Non-GAAP operating marginfiscal year 2026approximately 23.5-24%
Adjusted EBITDA marginfiscal year 2026approximately 31.5-32%

Key takeaways

  1. CONNECT trial supports CGM for non-insulin type 2

    Dexcom reported that CGM use among people with type 2 diabetes not using insulin produced clinically meaningful, statistically significant improvements in glucose control versus routine care. This evidence underpins the push into a much larger patient group.

  2. Stelo app relaunched with AI insights

    Dexcom started rolling out a reimagined Stelo experience with a more consumer-friendly feel, AI-driven insights and enhanced food logging. It signals deeper investment in the over-the-counter consumer segment.

  3. Nutrisense acquisition completed in the quarter

    Dexcom completed its acquisition of Nutrisense during the second quarter, adding to its consumer and wellness-oriented glucose offerings. Acquired non-CGM revenue was only $0.2 million, so it is early.

  4. G7 15 Day conversion and international clearance

    Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end, and Health Canada was the first international regulator to clear it. The product also contributes to expected gross margin gains.

  5. Payer coverage broadens, CMS decision pending

    Dexcom now has coverage for all people with diabetes across the 4 largest commercial PBMs, and expects to hear back from CMS before the end of this year. Coverage decisions are the main gate to the roughly 9 million covered but non-using people in the U.S.

Charts

Revenue$1.3B+13.1% y/yQ2 2026
Q4 2024: $1.1B (worked out from the annual figure)Q4 ’24$1.1BQ1 2025: $1.0BQ1 ’25$1.0BQ2 2025: $1.2BQ2 ’25$1.2BQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.3B (worked out from the annual figure)Q4 ’25$1.3BQ1 2026: $1.2BQ1 ’26$1.2BQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $1.3BQ3 ’26$1.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$1.1B *
Q1 2025$1.0B
Q2 2025$1.2B
Q3 2025$1.2B
Q4 2025$1.3B *
Q1 2026$1.2B
Q2 2026$1.3B
Q3 2026$1.3B
Diluted EPS (GAAP)$0.64+42.2% y/yQ2 2026
Q1 2025: $0.27Q1 ’25$0.27Q2 2025: $0.45Q2 ’25$0.45Q3 2025: $0.70Q3 ’25$0.70Q1 2026: $0.51Q1 ’26$0.51Q2 2026: $0.64Q2 ’26$0.64Q3 2026: $0.72Q3 ’26$0.72
Data
Q1 2025$0.27
Q2 2025$0.45
Q3 2025$0.70
Q1 2026$0.51
Q2 2026$0.64
Q3 2026$0.72

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin24.3%+5.9 pts y/yQ2 2026
Q4 2024: 17.0%Q4 ’2417.0%Q1 2025: 12.9%Q1 ’2512.9%Q2 2025: 18.4%Q2 ’2518.4%Q3 2025: 20.1%Q3 ’2520.1%Q4 2025: 25.6%Q4 ’2525.6%Q1 2026: 21.4%Q1 ’2621.4%Q2 2026: 24.3%Q2 ’2624.3%Q3 2026: 24.3%Q3 ’2624.3%
Data
Q4 202417.0%
Q1 202512.9%
Q2 202518.4%
Q3 202520.1%
Q4 202525.6%
Q1 202621.4%
Q2 202624.3%
Q3 202624.3%
Free cash flow$184.5M−11.7% y/yQ2 2026
Q4 2024: $176.8MQ4 ’24$176.8MQ1 2025: $96.8MQ1 ’25$96.8MQ2 2025: $208.9MQ2 ’25$208.9MQ3 2025: $579.4MQ3 ’25$579.4MQ4 2025: $192.1MQ4 ’25$192.1MQ1 2026: $449.0MQ1 ’26$449.0MQ2 2026: $184.5MQ2 ’26$184.5MQ3 2026: $272.7MQ3 ’26$272.7M
Data
Q4 2024$176.8M
Q1 2025$96.8M
Q2 2025$208.9M
Q3 2025$579.4M
Q4 2025$192.1M
Q1 2026$449.0M
Q2 2026$184.5M
Q3 2026$272.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What did Dexcom's CONNECT trial show?

It showed that CGM use among people with type 2 diabetes not using insulin led to clinically meaningful and statistically significant improvements in glucose control compared with routine care. Dexcom says it reinforces confidence in its long-range plan.

What is new with Dexcom's Stelo?

Dexcom began launching a fully reimagined Stelo app with a more consumer-friendly feel, new AI-driven insights and enhanced food logging. It also completed the Nutrisense acquisition during the quarter.

How far along is the G7 15 Day rollout?

Dexcom is on track to convert nearly 50% of its U.S. customer base to G7 15 Day by year end. Health Canada became the first international regulator to clear it.

How large is the untapped U.S. opportunity Dexcom cites?

Approximately 9 million people in the U.S. have coverage for CGM but are not yet using it. Coverage now spans all people with diabetes across the 4 largest commercial PBMs.

What did Dexcom lay out at Investor Day?

Dexcom hosted its 2026 Investor Day at its Arizona manufacturing facility, highlighting its market opportunity, strategy and innovation efforts. It introduced a new long-term financial outlook through 2030.